Literature DB >> 8543497

A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.

H C Kelly1, M Hutchison, S J Haworth.   

Abstract

The pharmacokinetics of meropenem were determined in healthy volunteers after intravenous injection over 5 min or iv infusion over 30 min. Five volunteers received meropenem 500 mg and six volunteers received 1000 mg. For both doses, administration over 5 rather than 30 min doubled the plasma concentrations observed at the end of the dosing period. Comparison of the other data derived from the two modes of administration indicated that rapid administration of meropenem did not appreciably alter its disposition pharmacokinetics. Plasma clearance, renal clearance, non-renal clearance, terminal half-life and volume of distribution were unchanged. Within 1 h of dosing, the plasma concentrations were very similar indicating that dosing over either time period would result in similar antimicrobial cover and thus should not affect efficacy. There were no changes in tolerability of meropenem associated with more rapid administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543497     DOI: 10.1093/jac/36.suppl_a.35

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.

Authors:  H K Jones; H C Kelly; M Hutchison; R A Yates; F Ross; C Lomax; S Freestone; D Webb
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.441

2.  Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.

Authors:  A A Firsov; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 3.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Single-Center Pharmacokinetic Study and Simulation of a Low Meropenem Concentration in Brain-Dead Organ Donors.

Authors:  Jae-Myeong Lee; Joo Won Lee; Tae Seok Jeong; Eun Sook Bang; So Hee Kim
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

5.  Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

Authors:  W A Krueger; T H Schroeder; M Hutchison; E Hoffmann; H J Dieterich; A Heininger; C Erley; A Wehrle; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

7.  Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

Authors:  Wolfgang A Krueger; Jurgen Bulitta; Martina Kinzig-Schippers; Cornelia Landersdorfer; Ulrike Holzgrabe; Kurt G Naber; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem.

Authors:  C Ponte; A Parra; E Nieto; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Penetration of meropenem in lung, bronchial mucosa, and pleural tissues.

Authors:  B Byl; F Jacobs; I Roucloux; P de Franquen; M Cappello; J P Thys
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

Review 10.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.